Seres Therapeutics Inc (NASDAQ: MCRB) has experienced a rise in its stock price by 3.48 compared to its previous closing price of 0.81. However, the company has seen a fall of -6.09% in its stock price over the last five trading days. globenewswire.com reported 2025-01-16 that CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company’s previously announced sale of its VOWST business to Société des Produits Nestlé S.A (SPN, and with certain of its affiliates, collectively, Nestlé Health Science). This installment payment was expected as Seres is fulfilling its transition obligations.
Is It Worth Investing in Seres Therapeutics Inc (NASDAQ: MCRB) Right Now?
The 36-month beta value for MCRB is at 2.09. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for MCRB is 124.81M, and currently, shorts hold a 16.23% of that float. The average trading volume for MCRB on January 30, 2025 was 2.74M shares.
MCRB’s Market Performance
MCRB stock saw a decrease of -6.09% in the past week, with a monthly decline of -6.06% and a quarterly a decrease of 19.01%. The volatility ratio for the week is 9.32%, and the volatility levels for the last 30 days are 9.11% for Seres Therapeutics Inc (MCRB). The simple moving average for the past 20 days is 0.33% for MCRB’s stock, with a -6.39% simple moving average for the past 200 days.
Analysts’ Opinion of MCRB
Oppenheimer, on the other hand, stated in their research note that they expect to see MCRB reach a price target of $12. The rating they have provided for MCRB stocks is “Outperform” according to the report published on June 26th, 2023.
JP Morgan gave a rating of “Neutral” to MCRB, setting the target price at $7 in the report published on April 21st of the previous year.
MCRB Trading at -1.10% from the 50-Day Moving Average
After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.55% of loss for the given period.
Volatility was left at 9.11%, however, over the last 30 days, the volatility rate increased by 9.32%, as shares sank -0.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +40.28% upper at present.
During the last 5 trading sessions, MCRB fell by -6.37%, which changed the moving average for the period of 200-days by +26.87% in comparison to the 20-day moving average, which settled at $0.8303. In addition, Seres Therapeutics Inc saw 0.25% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MCRB starting from DesRosier Thomas, who sale 878 shares at the price of $0.54 back on Nov 18 ’24. After this action, DesRosier Thomas now owns 135,192 shares of Seres Therapeutics Inc, valued at $475 using the latest closing price.
von Moltke Lisa, the See Remarks of Seres Therapeutics Inc, sale 977 shares at $0.54 during a trade that took place back on Nov 18 ’24, which means that von Moltke Lisa is holding 32,415 shares at $528 based on the most recent closing price.
Stock Fundamentals for MCRB
Current profitability levels for the company are sitting at:
- -2214.05 for the present operating margin
- -108.88 for the gross margin
The net margin for Seres Therapeutics Inc stands at -398.05. The total capital return value is set at -1.24. Equity return is now at value -3758.21, with -60.50 for asset returns.
Based on Seres Therapeutics Inc (MCRB), the company’s capital structure generated 0.8 points at debt to capital in total, while cash flow to debt ratio is standing at -1.68. The debt to equity ratio resting at 3.91. The interest coverage ratio of the stock is -11.67.
Currently, EBITDA for the company is -94.31 million with net debt to EBITDA at -0.19. When we switch over and look at the enterprise to sales, we see a ratio of 2626.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.12.
Conclusion
In conclusion, Seres Therapeutics Inc (MCRB) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
